In a Naples hospital, surgeons cut open the carotid arteries of 257 patients to scrape out the fatty plaque that was strangling blood flow to their brains. When researchers ran that plaque through an electron microscope, they found something that had no business being there: jagged fragments of polyethylene and polyvinyl chloride, the same plastics used in shopping bags, food packaging and PVC pipe, embedded in the arterial walls of 150 patients. Over the next 34 months, those 150 patients were 4.5 times more likely to suffer a heart attack, stroke, or die than the ones whose plaque was plastic-free.
The study landed in the New England Journal of Medicine in March 2024, and cardiologists are still arguing about what it means.
The number nobody expected
Raffaele Marfella and his team at the University of Campania had set out to do something modest: recruit patients scheduled for carotid endarterectomy — a routine procedure to clear plaque from the neck arteries — and see whether the debris they pulled out contained any of the microplastic contamination that had been showing up in oceans, soil, and, more recently, human blood.
They expected to find some. They did not expect to find it in 58% of patients. And they certainly did not expect the follow-up numbers.
Of the 150 patients with microplastics and nanoplastics lodged in their plaque, 30 went on to have a heart attack, non-fatal stroke, or die from any cause within 34 months of surgery. Among the 107 patients whose plaque was clean, only eight did. The hazard ratio came out to 4.53, with a 95% confidence interval that did not brush zero. The finding survived adjustment for age, sex, smoking status, diabetes, cholesterol, blood pressure, and every other cardiovascular risk factor the researchers threw at it.
That is the kind of effect size that, in cardiology, usually attaches to things like uncontrolled hypertension or a family history of early coronary disease. Not to a substance that most doctors, until recently, considered inert.
What the plastic was doing there
The mechanism, insofar as anyone understands it, tracks with the way atherosclerosis already works. Arterial plaque begins as a slow-motion failure of the endothelium — the single-cell lining that keeps blood on one side of the vessel wall and everything else on the other. Low-density lipoprotein particles slip through, get oxidised, and summon monocytes that mature into macrophages and gorge themselves on lipid until they turn into foam cells. Foam cells die. Their debris forms a necrotic core. A fibrous cap grows over the top. When the cap thins and breaks, the contents spill into the bloodstream and a clot forms. That clot is what a heart attack or stroke is, mechanically speaking. The Nature Research Intelligence summary of plaque vulnerability lays out the cascade in detail.
Nanoplastic particles, being smaller than a single cell, appear to slip through the endothelium the same way LDL does. Once inside the intima, they seem to intensify the inflammatory response — recruiting more macrophages, driving more foam cell death, thinning the fibrous cap. The Marfella group found that patients with microplastics in their plaque had elevated levels of inflammatory markers including interleukin-18 and tumour necrosis factor-alpha, both of which are known to destabilise arterial walls.
The plastic is not causing atherosclerosis from scratch. It is accelerating a disease process that was already underway.
Naples was not a fluke
The obvious question after any single study is whether anyone can replicate it. In April 2025, Ross Clark, a vascular surgeon-scientist at the University of New Mexico, presented data at the American Heart Association’s Vascular Discovery Scientific Sessions in Baltimore. His team had built on the Italian work with a smaller cohort — fewer than 50 patients — and compared three groups: people with healthy carotid arteries, people with plaque but no symptoms, and people who had already suffered a stroke, transient ischaemic attack, or temporary vision loss.
The gradient was steep. According to ScienceDaily’s reporting on the Baltimore presentation, plaque from symptomatic patients contained roughly 51 times more micronanoplastic material than the arteries of the healthy control group. Plaque from asymptomatic patients sat in between.
Karen Furie, chair of neurology at Brown University’s Warren Alpert Medical School, noted in a statement that plastic exposure has not traditionally been considered a modifiable stroke risk factor. Furie suggested the finding could represent a new avenue for stroke prevention research. Furie was not involved in the New Mexico work.
Clark himself was more cautious. His team’s method — pyrolysis gas chromatography-mass spectrometry — burns tissue samples down to their molecular signatures, and lipids in arterial plaque can produce signatures that look uncomfortably like polyethylene. Clark told the conference that his team’s methods are designed to address concerns about lipid interference in the analysis, according to News Tribune coverage. Clark acknowledged that future discoveries could alter interpretation of the findings.
The exposure math
The headline figure that circulated after the WWF-commissioned 2019 study — that the average person swallows about 5 grams of plastic a week, roughly the weight of a credit card — has been picked apart by other researchers and does not hold up to close scrutiny. But the direction of travel is not in dispute. Plastic particles have now been documented in human blood, breast milk, placental tissue, testicular tissue, and, most recently, brain tissue.
A February 2026 study covered by ScienceDaily found microplastics in nine out of ten prostate cancer tumours examined, at higher concentrations in cancerous tissue than in adjacent healthy tissue. The researchers stopped short of claiming causation. They did not need to. The pattern — plastic showing up preferentially in diseased tissue across multiple organ systems — is the signal that keeps triggering new grant applications.
Clark, in Baltimore, noted that consumers often mistakenly believe microplastics primarily come from direct contact with plastic items like utensils and packaging. He explained that the particles are actually already present in food and water supplies before packaging.
Why cardiology is nervous
Cardiovascular disease is a leading cause of death worldwide. The field has spent four decades identifying modifiable risk factors — smoking, LDL cholesterol, hypertension, diabetes, obesity, sedentary behaviour — and building interventions around each one.
A new modifiable risk factor with a hazard ratio above 4 is not a small addition to the list. It is a rewriting of the list.
The problem is that nobody yet knows what a clinical intervention would look like. You cannot prescribe less plastic the way you prescribe less salt. Regulatory action on plastic production is negotiated at international levels, but binding agreements on production caps remain elusive. The petrochemical industry, which supplies the feedstock for plastic production, has resisted upstream limits and pushed the conversation toward recycling and waste management instead.
Meanwhile, plaque keeps forming, and now it keeps forming with plastic inside it.
The gap between signal and proof
The honest scientific position, in 2026, is that association is not causation and 257 patients from a single Italian hospital is not a global cohort. Marfella’s team acknowledged as much in the original paper. Clark repeats the caveat every time he presents his own data. It is possible that microplastics in plaque are a marker of some other exposure that is doing the actual harm — that they are the fingerprint at the crime scene rather than the weapon.
What has changed is the burden of proof. For decades, the assumption behind consumer plastic — that it was inert, that it passed through, that whatever fragments did stick around were biologically irrelevant — sat on no particular evidence base. It was simply the default. That default is now being tested against tissue samples, and the tissue samples keep failing to cooperate.
Silicon Canals has previously covered how occupational psychology research keeps upending intuitive assumptions about health, and the microplastics story is following a similar arc: a background variable that everyone treated as neutral turns out, on inspection, to be doing something.
What follows the finding
The Marfella paper triggered a wave of follow-up research that is still being funded and staffed. The Italian group is running a larger prospective cohort. Clark’s New Mexico team is working on the immunology — specifically how macrophages behave in plaques with high plastic loads versus low ones. Groups in South Korea, Germany, and the Netherlands have started their own carotid tissue studies. The methodological arguments about pyrolysis gas chromatography will resolve themselves either through better separation techniques or through complementary imaging methods that can visualise particles directly in tissue.
The three-year follow-up on the 257 Naples patients will, in time, become a five-year and a ten-year follow-up. If the hazard ratio holds, the case for classifying micronanoplastic exposure as a cardiovascular risk factor will move from tentative to conventional. If it collapses — if a confounder emerges, if the measurement turns out to be contaminated by lipid signatures — the field will retreat and the plastic industry will point to the retreat.
Neither outcome changes what is already true about the 150 patients whose plaque contained plastic. Something got inside them. It found a place to settle. It is still there.
